CY1120888T1 - Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες - Google Patents
Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντεςInfo
- Publication number
- CY1120888T1 CY1120888T1 CY181100850T CY181100850T CY1120888T1 CY 1120888 T1 CY1120888 T1 CY 1120888T1 CY 181100850 T CY181100850 T CY 181100850T CY 181100850 T CY181100850 T CY 181100850T CY 1120888 T1 CY1120888 T1 CY 1120888T1
- Authority
- CY
- Cyprus
- Prior art keywords
- pharmaceutical compositions
- active agents
- compositions including
- including active
- transparent pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει συνθέσεις και μεθόδους για παροχή κατακρατημένης αποδέσμευσης ενός ενεργού παράγοντα μέσα από το δέρμα ενός υποκειμένου, όπου μια φαρμακευτική διαδερματική σύνθεση περιλαμβάνει τουλάχιστον έναν εστέρα λιπαρού οξέος και μια θεραπευτικώς αποτελεσματική ποσότητα ενεργού παράγοντα.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25524109P | 2009-10-27 | 2009-10-27 | |
EP09178762 | 2009-12-10 | ||
EP10768983.8A EP2493508B1 (en) | 2009-10-27 | 2010-10-27 | Transdermal pharmaceutical compositions comprising active agents |
PCT/EP2010/066283 WO2011051354A2 (en) | 2009-10-27 | 2010-10-27 | Transdermal pharmaceutical compositions comprising active agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120888T1 true CY1120888T1 (el) | 2019-12-11 |
Family
ID=42102488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY181100850T CY1120888T1 (el) | 2009-10-27 | 2018-08-13 | Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες |
Country Status (23)
Country | Link |
---|---|
US (2) | US10080760B2 (el) |
EP (2) | EP3360575B1 (el) |
JP (1) | JP5727494B2 (el) |
CN (1) | CN102686240B (el) |
AU (1) | AU2010311523B2 (el) |
BR (1) | BR112012010083B8 (el) |
CA (1) | CA2778689C (el) |
CY (1) | CY1120888T1 (el) |
DK (2) | DK2493508T3 (el) |
ES (2) | ES2685313T3 (el) |
FI (1) | FI3360575T3 (el) |
HR (2) | HRP20230482T1 (el) |
HU (2) | HUE039200T2 (el) |
IL (1) | IL219236A (el) |
LT (2) | LT3360575T (el) |
PL (2) | PL2493508T3 (el) |
PT (2) | PT2493508T (el) |
RS (2) | RS57596B1 (el) |
RU (2) | RU2639087C2 (el) |
SI (2) | SI2493508T1 (el) |
TR (1) | TR201811600T4 (el) |
WO (1) | WO2011051354A2 (el) |
ZA (1) | ZA201202855B (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
US10080760B2 (en) | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
US20120004204A1 (en) * | 2010-07-02 | 2012-01-05 | Biosante Pharmaceuticals, Inc. | Methods for treating sexual dysfunction while decreasing cardiovascular risk |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
RU2592370C9 (ru) * | 2014-04-24 | 2016-08-27 | Иван Иванович Дедов | Средство на основе дегидроэпиандростерона, способ его применения |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3370178A3 (en) | 2017-03-03 | 2018-12-19 | Tata Consultancy Services Limited | Method and system for in silico testing of actives on human skin |
RU2751037C1 (ru) * | 2020-04-03 | 2021-07-07 | Богдан Иванович Асатуров | Фармацевтическая композиция на основе аутобиокомпонентов мочи человека для трансдермального применения с лечебной или косметической целью |
CN111803469B (zh) * | 2020-07-15 | 2022-08-12 | 浙江海阁堂医药有限公司 | 一种含雌二醇透皮吸收缓释贴片及其制备方法 |
CN113730339B (zh) * | 2021-09-17 | 2023-08-22 | 中国药科大学 | 一种黄体酮缓释组合物及其应用 |
EP4308088A4 (en) * | 2021-11-08 | 2024-06-12 | Weiyong Li | TRANSDERMAL DRUG DELIVERY SYSTEM FOR DELIVERING DRUG TO A PATIENT |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1106455B (de) | 1959-05-29 | 1961-05-10 | Upjohn Co | Salbengrundlage |
FR2518879A1 (fr) | 1981-12-30 | 1983-07-01 | Besins Jean | Medicament a base d'oestradiol pour le traitement de la pathologie menopausique |
US4906169A (en) * | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
JPH0798935B2 (ja) | 1987-11-25 | 1995-10-25 | 有限会社野々川商事 | 品質劣化防止剤 |
DE68920109T2 (de) | 1988-10-11 | 1995-05-11 | Shire Holdings Ltd | Arzneimittelpräparat für perkutane Absorption. |
US5332577A (en) * | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
US5232703A (en) * | 1989-07-21 | 1993-08-03 | Izhak Blank | Estradiol compositions and methods for topical application |
DE69007886T2 (de) | 1989-07-21 | 1994-11-17 | Izhak Blank | Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung. |
PT99338A (pt) | 1990-10-29 | 1992-10-30 | Alza Corp | Processo para a preparacao de composicoes de farmacos anticoncepcionais administradas transdermicamente contendo uma mistura dum estrogeno e gestodeno e dispositivos para a sua administracao transdermica |
DE4227989A1 (de) | 1992-08-21 | 1994-06-09 | Schering Ag | Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel |
AU692504B2 (en) | 1993-12-27 | 1998-06-11 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
CN1106259A (zh) | 1994-02-05 | 1995-08-09 | 日东制药株式会社 | 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂 |
FR2732223B1 (fr) * | 1995-03-30 | 1997-06-13 | Sanofi Sa | Composition pharmaceutique pour administration transdermique |
US5902603A (en) * | 1995-09-14 | 1999-05-11 | Cygnus, Inc. | Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use |
JP3081531B2 (ja) * | 1996-03-22 | 2000-08-28 | 株式会社ヱビス科学研究所 | 手投げ消火液弾 |
US5762956A (en) | 1996-04-24 | 1998-06-09 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system and process |
IT1283102B1 (it) * | 1996-06-06 | 1998-04-07 | Permatec Nv | Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele |
RU2122396C1 (ru) | 1996-07-12 | 1998-11-27 | Валентина Александровна Андрюшина | Биологически-активная добавка в косметические изделия |
AU718811B2 (en) | 1996-10-30 | 2000-04-20 | Theratech, Inc. | Fatty acid esters of glycolic acid and its salts as permeation enhancers |
KR100215027B1 (ko) | 1997-01-27 | 1999-08-16 | 성재갑 | 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형 |
PT1510213E (pt) | 1997-11-10 | 2009-02-12 | Strakan Internat Ltd Uma Socie | Sistemas de melhoramento de penetração e reduzida irritação incluíndo testosterona |
EP1043020A1 (en) | 1997-12-25 | 2000-10-11 | Daiichi Pharmaceutical Co., Ltd. | Medicinal composition for percutaneous administration |
US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
AU8206401A (en) | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
KR100416646B1 (ko) | 2000-08-14 | 2004-02-05 | 구주제약주식회사 | 리도카인을 함유한 조루치료용 마이크로에멀젼 하이드로겔 제형의 약학 조성물 |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20040002482A1 (en) * | 2000-08-30 | 2004-01-01 | Dudley Robert E. | Androgen pharmaceutical composition and method for treating depression |
FR2814074B1 (fr) | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
JP2002212105A (ja) | 2001-01-22 | 2002-07-31 | Lion Corp | 水性皮膚外用剤組成物 |
WO2003028667A2 (en) * | 2001-10-04 | 2003-04-10 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
US20040072810A1 (en) * | 2001-11-07 | 2004-04-15 | Besins International Belgique | Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof |
WO2004091631A1 (en) * | 2002-03-15 | 2004-10-28 | Unimed Pharmaceuticals, Inc. | Androgen pharmaceutical composition and method for treating depression |
US6756050B2 (en) * | 2002-06-28 | 2004-06-29 | Ultra Biotech Limited | Dietary supplements for improving memory |
FR2848112B1 (fr) * | 2002-12-10 | 2007-02-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations |
FR2851470B1 (fr) * | 2003-02-20 | 2007-11-16 | Besins Int Belgique | Composition pharmaceutique pour administration transdermique ou transmuqueuse |
ES2456957T3 (es) * | 2003-04-01 | 2014-04-24 | Besins Healthcare Luxembourg Sarl | Tratamiento de cáncer de seno con 4-hidroxitamoxifen |
US20070196325A1 (en) * | 2004-06-07 | 2007-08-23 | Jie Zhang | Compositions and methods for dermally treating infections |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
CA2582174C (en) * | 2004-10-14 | 2013-01-29 | Laboratoires Besins International | 4-hydroxy tamoxifen gel formulations |
EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
US20070082039A1 (en) * | 2004-10-18 | 2007-04-12 | Jones Gerald S Jr | Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids |
US20080058299A1 (en) | 2005-04-12 | 2008-03-06 | Dudley Robert E | Method of treating or preventing bone deterioration or osteoporosis |
JP2008539236A (ja) * | 2005-04-25 | 2008-11-13 | ドウ ファーマシューティカル サイエンシーズ | 乾癬を治療するためのクロベタゾールスプレー製剤の使用 |
WO2007038496A2 (en) * | 2005-09-27 | 2007-04-05 | Chemic Laboratories, Inc. | Synthesis of fatty alcohol esters of hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers |
EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
EP3656376A1 (en) * | 2008-12-11 | 2020-05-27 | Besins Healthcare Luxembourg SARL | Transdermal pharmaceutical compositions comprising a serm |
US10080760B2 (en) | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
-
2010
- 2010-10-26 US US12/912,310 patent/US10080760B2/en active Active
- 2010-10-27 WO PCT/EP2010/066283 patent/WO2011051354A2/en active Application Filing
- 2010-10-27 PT PT10768983T patent/PT2493508T/pt unknown
- 2010-10-27 HR HRP20230482TT patent/HRP20230482T1/hr unknown
- 2010-10-27 DK DK10768983.8T patent/DK2493508T3/en active
- 2010-10-27 PL PL10768983T patent/PL2493508T3/pl unknown
- 2010-10-27 RS RS20180963A patent/RS57596B1/sr unknown
- 2010-10-27 PT PT181636598T patent/PT3360575T/pt unknown
- 2010-10-27 CA CA2778689A patent/CA2778689C/en active Active
- 2010-10-27 AU AU2010311523A patent/AU2010311523B2/en active Active
- 2010-10-27 ES ES10768983.8T patent/ES2685313T3/es active Active
- 2010-10-27 EP EP18163659.8A patent/EP3360575B1/en active Active
- 2010-10-27 SI SI201031737T patent/SI2493508T1/sl unknown
- 2010-10-27 EP EP10768983.8A patent/EP2493508B1/en active Active
- 2010-10-27 CN CN201080059696.5A patent/CN102686240B/zh active Active
- 2010-10-27 HU HUE10768983A patent/HUE039200T2/hu unknown
- 2010-10-27 FI FIEP18163659.8T patent/FI3360575T3/fi active
- 2010-10-27 SI SI201032129T patent/SI3360575T1/sl unknown
- 2010-10-27 ES ES18163659T patent/ES2945590T3/es active Active
- 2010-10-27 RS RS20230352A patent/RS64190B1/sr unknown
- 2010-10-27 LT LTEP18163659.8T patent/LT3360575T/lt unknown
- 2010-10-27 HU HUE18163659A patent/HUE062026T2/hu unknown
- 2010-10-27 JP JP2012535814A patent/JP5727494B2/ja active Active
- 2010-10-27 RU RU2012121708A patent/RU2639087C2/ru active
- 2010-10-27 TR TR2018/11600T patent/TR201811600T4/tr unknown
- 2010-10-27 RU RU2017131709A patent/RU2017131709A/ru unknown
- 2010-10-27 BR BR112012010083A patent/BR112012010083B8/pt active IP Right Grant
- 2010-10-27 PL PL18163659.8T patent/PL3360575T3/pl unknown
- 2010-10-27 LT LTEP10768983.8T patent/LT2493508T/lt unknown
- 2010-10-27 DK DK18163659.8T patent/DK3360575T3/da active
-
2012
- 2012-04-17 IL IL219236A patent/IL219236A/en active IP Right Grant
- 2012-04-18 ZA ZA2012/02855A patent/ZA201202855B/en unknown
-
2018
- 2018-08-13 CY CY181100850T patent/CY1120888T1/el unknown
- 2018-08-23 US US16/111,098 patent/US11040043B2/en active Active
- 2018-08-23 HR HRP20181346TT patent/HRP20181346T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120888T1 (el) | Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες | |
CY1123549T1 (el) | Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης | |
CY1117847T1 (el) | Φαρμακευτικο σκευασμα που περιλαμβανει ενα ή περισσοτερους εστερες φουμαρικου οξεος σε μητρα διαβρωσης | |
NI201200038A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
CL2007002095A1 (es) | Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composicion empacada; metodo para esterilizarla; util para cicatrizar tejido donde la dermis se ha desgarrado. | |
GT201200276A (es) | Combinaciones de compuestos activos | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
MX2012003555A (es) | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. | |
UA118177C2 (uk) | Композиція для лікування гіперліпідемії, яка містить похідну оксинтомодуліну | |
BR112012007747A2 (pt) | Compostos heterocíclicos úteis como inibidores de pdk1, sua composição farmacêutica e seus usos | |
CL2007002228A1 (es) | Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado. | |
BRPI0917017B8 (pt) | inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos | |
BR112013008601A8 (pt) | Formulações de emulsão de clevidipina contendo agentes antimicrobianos | |
ECSP12012208A (es) | Formulaciones orales y sales lipofílicas de metilnaltrexona | |
UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
BR112014020271A8 (pt) | Composição farmacêutica e métodos para diminuir a frequência de micção em paciente | |
BR112012007798A2 (pt) | microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas | |
FR2915683B1 (fr) | Formulations pharmaceutiques auto-precipitantes pour la liberation modifiee de principe actif | |
UA96794C2 (ru) | Глюкокортикоиды, способ их применения, способ лечения и фармацевтическая композиция на их основе | |
CO6280474A2 (es) | Composicion farmaceutica para el tratamiento de la eyaculacion precoz | |
CL2009001841A1 (es) | Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto. | |
MX353580B (es) | Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel. | |
CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. | |
BR112013019924A8 (pt) | Composições para cuidado oral |